Aron Mosnaim

Last updated
Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry. 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID   4716838. S2CID   8349615.
  • Sabelli, Hector C.; Mosnaim, A. David (June 1974). "Phenylethylamine Hypothesis of Affective Behavior". American Journal of Psychiatry. 131 (6): 695–699. doi:10.1176/ajp.131.6.695. PMID   4827802.
  • Wolf, Marion E; Alavi, Afshin; Mosnaim, Aron D (March 1988). "Posttraumatic stress disorder in vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine". Biological Psychiatry. 23 (6): 642–644. doi:10.1016/0006-3223(88)90011-x. PMID   3355879. S2CID   40512787.
  • Mosnaim, Aron D.; Ranade, Vasant V.; Wolf, Marion E.; Puente, Javier; Antonieta Valenzuela, M. (May 2006). "Phenothiazine Molecule Provides the Basic Chemical Structure for Various Classes of Pharmacotherapeutic Agents". American Journal of Therapeutics. 13 (3): 261–273. doi:10.1097/01.mjt.0000212897.20458.63. PMID   16772768.

    • Related Research Articles

    Post-traumatic stress disorder (PTSD) is a mental and behavioral disorder that develops from experiencing a traumatic event, such as sexual assault, warfare, traffic collisions, child abuse, domestic violence, or other threats on a person's life or well-being. Symptoms may include disturbing thoughts, feelings, or dreams related to the events, mental or physical distress to trauma-related cues, attempts to avoid trauma-related cues, alterations in the way a person thinks and feels, and an increase in the fight-or-flight response. These symptoms last for more than a month after the event. Young children are less likely to show distress, but instead may express their memories through play. A person with PTSD is at a higher risk of suicide and intentional self-harm.

    <span class="mw-page-title-main">Typical antipsychotic</span> Class of drugs

    Typical antipsychotics are a class of antipsychotic drugs first developed in the 1950s and used to treat psychosis. Typical antipsychotics may also be used for the treatment of acute mania, agitation, and other conditions. The first typical antipsychotics to come into medical use were the phenothiazines, namely chlorpromazine which was discovered serendipitously. Another prominent grouping of antipsychotics are the butyrophenones, an example of which is haloperidol. The newer, second-generation antipsychotics, also known as atypical antipsychotics, have largely supplanted the use of typical antipsychotics as first-line agents due to the higher risk of movement disorders in the latter.

    <span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

    The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

    <span class="mw-page-title-main">Benzatropine</span> Medication for movement disorders

    Benzatropine (INN), known as benztropine in the United States and Japan, is a medication used to treat movement disorders like parkinsonism and dystonia, as well as extrapyramidal side effects of antipsychotics, including akathisia. It is not useful for tardive dyskinesia. It is taken by mouth or by injection into a vein or muscle. Benefits are seen within two hours and last for up to ten hours.

    <span class="mw-page-title-main">Phenelzine</span> Antidepressant

    Phenelzine, sold under the brand name Nardil, among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class which is primarily used as an antidepressant and anxiolytic. Along with tranylcypromine and isocarboxazid, phenelzine is one of the few non-selective and irreversible MAOIs still in widespread clinical use.

    <span class="mw-page-title-main">Tardive dyskinesia</span> Neurological disorder featuring involuntary, repetitive body movements

    Tardive dyskinesia (TD) is a disorder that results in involuntary repetitive body movements, which may include grimacing, sticking out the tongue or smacking the lips. Additionally, there may be chorea or slow writhing movements. In about 20% of people with TD, the disorder interferes with daily functioning. If TD is present in the setting of a long-term drug therapy, reversibility can be determined primarily by severity of symptoms and how long symptoms have been present before the long-term drug has been stopped.

    <span class="mw-page-title-main">Phenethylamine</span> Organic compound, a stimulant in humans

    Phenethylamine (PEA) is an organic compound, natural monoamine alkaloid, and trace amine, which acts as a central nervous system stimulant in humans. In the brain, phenethylamine regulates monoamine neurotransmission by binding to trace amine-associated receptor 1 (TAAR1) and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons. To a lesser extent, it also acts as a neurotransmitter in the human central nervous system. In mammals, phenethylamine is produced from the amino acid L-phenylalanine by the enzyme aromatic L-amino acid decarboxylase via enzymatic decarboxylation. In addition to its presence in mammals, phenethylamine is found in many other organisms and foods, such as chocolate, especially after microbial fermentation.

    <span class="mw-page-title-main">Metoclopramide</span> Medication

    Metoclopramide is a medication used for stomach and esophageal problems. It is commonly used to treat and prevent nausea and vomiting, to help with emptying of the stomach in people with delayed stomach emptying, and to help with gastroesophageal reflux disease. It is also used to treat migraine headaches.

    <span class="mw-page-title-main">Hydroxyzine</span> Antihistamine drug

    Hydroxyzine, sold under the brand names Atarax and Vistaril among others, is an antihistamine medication. It is used in the treatment of itchiness, insomnia, anxiety, and nausea, including that due to motion sickness. It is used either by mouth or injection into a muscle.

    Acute stress reaction and acute stress disorder (ASD) is a psychological response to a terrifying, traumatic or surprising experience. Combat stress reaction (CSR) is a similar response to the trauma of war. The reactions may include but are not limited to intrusive or dissociative symptoms, and reactivity symptoms such as avoidance or arousal. It may be exhibited for days or weeks after the traumatic event. If the condition is not correctly addressed, it may develop into post-traumatic stress disorder (PTSD).

    Biological psychiatry or biopsychiatry is an approach to psychiatry that aims to understand mental disorder in terms of the biological function of the nervous system. It is interdisciplinary in its approach and draws on sciences such as neuroscience, psychopharmacology, biochemistry, genetics, epigenetics and physiology to investigate the biological bases of behavior and psychopathology. Biopsychiatry is the branch of medicine which deals with the study of the biological function of the nervous system in mental disorders.

    <span class="mw-page-title-main">Sulpiride</span> Atypical antipsychotic

    Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Asia, Central America, Europe, South Africa and South America. Levosulpiride is its purified levo-isomer and is sold in India for similar purpose. It is not approved in the United States, Canada, or Australia. The drug is chemically and clinically similar to amisulpride.

    A sympatholytic (sympathoplegic) drug is a medication that opposes the downstream effects of postganglionic nerve firing in effector organs innervated by the sympathetic nervous system (SNS). They are indicated for various functions; for example, they may be used as antihypertensives. They are also used to treat anxiety, such as generalized anxiety disorder, panic disorder and PTSD. In some cases, such as with guanfacine, they have also shown to be beneficial in the treatment of ADHD.

    <span class="mw-page-title-main">Dopamine beta-hydroxylase</span> Mammalian protein found in Homo sapiens

    Dopamine beta-hydroxylase (DBH), also known as dopamine beta-monooxygenase, is an enzyme that in humans is encoded by the DBH gene. Dopamine beta-hydroxylase catalyzes the conversion of dopamine to norepinephrine.

    <span class="mw-page-title-main">Tiapride</span> Antipsychotic medication

    Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects.

    Tardive dysmentia is a rarely used term introduced in a 1983 paper to describe "changes in affect, activation level, and interpersonal interaction", and hypothesized to be caused by long-term exposure to neuroleptic drugs in the same way as the much better-known syndrome of tardive dyskinesia. Several papers in the following years discussed the validity of the concept, and this small literature was reviewed in a 1993 publication by M. S. Myslobodsky, who drew attention to the "possibility that the syndrome of dysmentia is composed of occasional excessive emotional reactivity, enhanced responsiveness to environmental stimuli, and indifference to or reduced awareness of the patient's abnormal involuntary movements", but concluded that the pathophysiology was uncertain. Since then, the term has fallen into disuse, receiving at most only passing mentions in the literature.

    The C957T gene polymorphism is a synonymous mutation located within the 957th base pair of the DRD2 gene. This base pair is located in exon 7. Most synonymous mutations are silent. However, the C957T mutation is an exception to this rule. While the 957C allele codes for the same polypeptide as the 957T allele, the conformation of 957T messenger RNA differs from the conformation of 957C messenger RNA. 957T messenger RNA is less stable and more prone to degradation. Dopamine D2 receptor expression is increased among individuals who carry the 957T allele compared to individuals who carry the 957C allele.

    Dopamine supersensitivity psychosis is a hypothesis that attempts to explain the phenomenon in which psychosis occurs despite treatment with escalating doses of antipsychotics. Dopamine supersensitivity may be caused by the dopamine receptor D2 antagonizing effect of antipsychotics, causing a compensatory increase in D2 receptors within the brain that sensitizes neurons to endogenous release of the neurotransmitter dopamine. Because psychosis is thought to be mediated—at least in part—by the activity of dopamine at D2 receptors, the activity of dopamine in the presence of supersensitivity may paradoxically give rise to worsening psychotic symptoms despite antipsychotic treatment at a given dose. This phenomenon may co-occur with tardive dyskinesia, a rare movement disorder that may also be due to dopamine supersensitivity.

    <span class="mw-page-title-main">Deutetrabenazine</span> Chemical compound

    Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia.

    <span class="mw-page-title-main">Meaghan Creed</span> Canadian Neuroscientist

    Meaghan Creed is a Canadian neuroscientist and associate professor of anesthesiology at Washington University in St. Louis. Creed has conducted research on understanding and optimizing deep brain stimulation in the basal ganglia for the treatment of neurological and psychiatric disorders. Her work has been recognized at the national and international level by Pfizer, the American Association for the Advancement of Science (AAAS), the Whitehall Foundation, Brain and Behavior Research Foundation and the Rita Allen Foundation.

    References

    1. 1 2 3 "Aron D. Mosnaim, PhD". Rosalind Franklin University.
    2. ↑ Noncatecholic phenylethylamines. OCLC   3516955.[ page needed ][ non-primary source needed ]
    3. ↑ Kinzie, J. David (October 1991). "Posttraumatic stress disorder: Etiology, phenomenology and treatment. By M. E. Wolf, and A. D. Mosnaim, editors. Washington, D.C.: American Psychiatric Press, Inc., 1990, 270 pages". Journal of Traumatic Stress. 4 (4): 607–608. doi:10.1002/jts.2490040416.
    4. ↑ Wolf, Marion E.; Mosnaim, Aron D. (1988). Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. American Psychiatric Press. ISBN   978-0-88048-176-2. OCLC   17953812.[ page needed ][ non-primary source needed ]
    5. ↑ Mosnaim, A.D.; Wolf, M.E.; Saavedra, I.; Amaro, A.M.; Cordano, G.; Nonhebel, D.C. (January 1973). "Reaction of cupric(ii) halides with organic compounds-VIII pyrene and some 3-substituted pyrenes". Tetrahedron Letters. 14 (17): 1491–1494. doi:10.1016/S0040-4039(01)95980-5.[ non-primary source needed ]
    6. ↑ Mosnaim, AD; Inwang, EE; Sugerman, JH; DeMartini, WJ; Sabelli, HC (June 1973). "Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression". Biological Psychiatry. 6 (3): 235–57. PMID   4732254.[ non-primary source needed ]
    7. ↑ Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry. 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID   4716838. S2CID   8349615.[ non-primary source needed ]
    8. ↑ Mosnaim, Aron D.; Wolf, Marion E. (1978). Noncatecholic Phenylethylamines. M. Dekker. ISBN   978-0-8247-6616-0.[ page needed ][ non-primary source needed ]
    9. ↑ Wolf, Marion E.; Mosnaim, A.D. (January 1983). "Phenylethylamine in neuropsychiatric disorders". General Pharmacology: The Vascular System. 14 (4): 385–390. doi:10.1016/0306-3623(83)90020-4. PMID   6352395.[ non-primary source needed ]
    10. ↑ Sabelli, H. C.; Vazquez, A. J.; Mosnaim, A. D.; Madrid-Pedemonte, L. (March 1974). "2-Phenylethylamine as a possible mediator for Δ9-tetrahydrocannabinol-induced stimulation". Nature. 248 (5444): 144–145. Bibcode:1974Natur.248..144S. doi:10.1038/248144a0. PMID   4274244. S2CID   4168572.[ non-primary source needed ]
    11. ↑ Mosnaim, Aron D.; Callaghan, Owen H.; Hudzik, Thomas; Wolf, Marion E. (April 2013). "Rat Brain-Uptake Index for Phenylethylamine and Various Monomethylated Derivatives". Neurochemical Research. 38 (4): 842–846. doi:10.1007/s11064-013-0988-1. PMID   23389662. S2CID   254860661.[ non-primary source needed ]
    12. ↑ Mosnaim, Aron D.; Wolf, Marion E.; III. O’Donnell, James J.; Hudzik, Thomas (3 July 2020). "β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice". Drug and Chemical Toxicology. 43 (4): 369–372. doi:10.1080/01480545.2018.1551899. PMID   30614291. S2CID   58557529.[ non-primary source needed ]
    13. ↑ Mosnaim, Aron D.; Puente, Javier; Saavedra, Rolando; Diamond, Seymour; Wolf, Marion E. (2003). "In vitro Human Plasma Leucine5-Enkephalin Degradation Is Inhibited by a Select Number of Drugs with the Phenothiazine Molecule in Their Chemical Structure". Pharmacology. 67 (1): 6–13. doi:10.1159/000066781. PMID   12444298. S2CID   22740728.[ non-primary source needed ]
    14. ↑ Mosnaim, Aron D.; Wolf, Marion E.; Chevesich, Jorge; Callaghan, Owen H.; Diamond, Seymour (July 1985). "Plasma Methionine Enkephalin Levels — A Biological Marker for Migraine?". Headache: The Journal of Head and Face Pain. 25 (5): 259–267. doi:10.1111/j.1526-4610.1985.hed2505259.x. PMID   4030316. S2CID   35728043.[ non-primary source needed ]
    15. ↑ Mosnaim, Aron D.; Diamond, Seymour; Freitag, Frederick; Chevesich, Jorge; Wolf, Marion E.; Solomon, Glen (June 1987). "Plasma and Platelet Methionine-Enkephalin Levels in Chronic Cluster Patients During an Acute Headache Episode". Headache: The Journal of Head and Face Pain. 27 (6): 325–328. doi:10.1111/j.1526-4610.1987.hed2706325.x. PMID   3654188. S2CID   29924147.[ non-primary source needed ]
    16. ↑ Mosnaim, A.D.; Freitag, F.; Karoum, F.; Wolf, M.E.; Diamond, S.; Salas, M.A. (April 1996). "Migraine and the contents of tyramine and phenylethylamine in food". Biological Psychiatry. 39 (7): 595. doi:10.1016/0006-3223(96)84270-3. S2CID   54244086.[ non-primary source needed ]
    17. ↑ Wolf, ME; Chevesich, J; Lehrer, E; Mosnaim, AD (October 1983). "The clinical association of tardive dyskinesia and drug-induced parkinsonism". Biological Psychiatry. 18 (10): 1181–8. PMID   6140032.[ non-primary source needed ]
    18. ↑ Wolf, Marion E.; Mosnaim, Aron D. (August 1984). "Identifying Subtypes of Tardive Dyskinesia". Psychiatric Services. 35 (8): 828–830. doi:10.1176/ps.35.8.828. PMID   6479919.[ non-primary source needed ]
    19. ↑ Wolf, Marion E.; Ryan, Joseph J.; Mosnaim, Aron D. (August 1983). "Cognitive functions in tardive dyskinesia". Psychological Medicine. 13 (3): 671–674. doi:10.1017/S0033291700048108. PMID   6137851. S2CID   26957713.[ non-primary source needed ]
    20. ↑ Wolf, ME; DeWolfe, AS; Ryan, JJ; Lips, O; Mosnaim, AD (September 1985). "Vulnerability to tardive dyskinesia". The Journal of Clinical Psychiatry. 46 (9): 367–8. PMID   2863257.[ non-primary source needed ]
    21. ↑ Wolf, M. E; Alavi, A.; Mosnaim, A. D. (1988). "Pain, dermatological and allergic conditions in post traumatic stress disorder". Pain, Dermatological and Allergic Conditions in Post Traumatic Stress Disorder. 13 (3): 237–240. INIST   7009885.[ non-primary source needed ]
    22. ↑ Maturana, Patricio; Puente, Javier; Miranda, Dante; Sepulveda, Cecilia; Wolf, Marion E.; Mosnaim, Aron D. (March 1991). "Natural killer cell activity in patients with septic shock". Journal of Critical Care. 6 (1): 42–45. doi:10.1016/0883-9441(91)90032-O.[ non-primary source needed ]
    23. ↑ Sepúlveda, Cecilia; Puente, Javier; Weinstein, Caroline; Wolf, Marion E.; Mosnaim, Aron D. (November 1997). "Enhancement of natural killer cell activity in HIV-1-infected subjects by a mixture of the calcium ionophore A23187 and the phorbol ester TPA: lack of response to a similar challenge with interleukin-2 or α-interferon". American Journal of Therapeutics. 4 (11): 413–422. doi:10.1097/00045391-199711000-00013. PMID   10423640. S2CID   42963577.[ non-primary source needed ]
    24. ↑ Puente, J; Carvajal, T; Parra, S; Miranda, D; Sepulveda, C; Wolf, ME; Mosnaim, AD (June 1993). "In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 31 (6): 271–275. PMID   8335423.[ non-primary source needed ]
    This page is based on this Wikipedia article
    Text is available under the CC BY-SA 4.0 license; additional terms may apply.
    Images, videos and audio are available under their respective licenses.
    Aron David Mosnaim
    Occupation(s) Neuroscientist, researcher, and academic
    Academic background
    Education PharmD degree
    PhD in Organic Chemistry
    Alma mater University of Chile
    University of Strathclyde